CeNeRx raises $4.85M for TriRima trial, CNS agents

12/15/2011 | Pharmaceutical Business Review Online

CeNeRx BioPharma has secured $4.85 million in funding from investors including L Capital Partners and Omega Funds. The company will use the money to finish its second-phase trial of TriRima, its new antidepressant formulation, and to advance agents for disorders of the central nervous system.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA